JP5412519B2 - キナーゼ阻害剤としてのピコリンアミド誘導体 - Google Patents

キナーゼ阻害剤としてのピコリンアミド誘導体 Download PDF

Info

Publication number
JP5412519B2
JP5412519B2 JP2011524408A JP2011524408A JP5412519B2 JP 5412519 B2 JP5412519 B2 JP 5412519B2 JP 2011524408 A JP2011524408 A JP 2011524408A JP 2011524408 A JP2011524408 A JP 2011524408A JP 5412519 B2 JP5412519 B2 JP 5412519B2
Authority
JP
Japan
Prior art keywords
added
tert
amino
methyl
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011524408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501314A (ja
Inventor
マシュー・ティ・バーガー
ハン・ウソク
ラン・ジオン
ジゼル・ニシグチ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5412519(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2012501314A publication Critical patent/JP2012501314A/ja
Application granted granted Critical
Publication of JP5412519B2 publication Critical patent/JP5412519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011524408A 2008-09-02 2009-08-31 キナーゼ阻害剤としてのピコリンアミド誘導体 Active JP5412519B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9366608P 2008-09-02 2008-09-02
US61/093,666 2008-09-02
US22566009P 2009-07-15 2009-07-15
US61/225,660 2009-07-15
PCT/EP2009/061205 WO2010026124A1 (en) 2008-09-02 2009-08-31 Picolinamide derivatives as kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013132978A Division JP5813701B2 (ja) 2008-09-02 2013-06-25 キナーゼ阻害剤としてのピコリンアミド誘導体

Publications (2)

Publication Number Publication Date
JP2012501314A JP2012501314A (ja) 2012-01-19
JP5412519B2 true JP5412519B2 (ja) 2014-02-12

Family

ID=41228825

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011524408A Active JP5412519B2 (ja) 2008-09-02 2009-08-31 キナーゼ阻害剤としてのピコリンアミド誘導体
JP2013132978A Active JP5813701B2 (ja) 2008-09-02 2013-06-25 キナーゼ阻害剤としてのピコリンアミド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013132978A Active JP5813701B2 (ja) 2008-09-02 2013-06-25 キナーゼ阻害剤としてのピコリンアミド誘導体

Country Status (39)

Country Link
US (4) US8329732B2 (he)
EP (1) EP2344474B1 (he)
JP (2) JP5412519B2 (he)
KR (1) KR101345920B1 (he)
CN (3) CN104311480A (he)
AU (1) AU2009289319C1 (he)
BR (1) BRPI0918268B1 (he)
CA (1) CA2734415C (he)
CL (1) CL2011000454A1 (he)
CO (1) CO6351725A2 (he)
CR (1) CR20110114A (he)
DK (1) DK2344474T3 (he)
DO (1) DOP2011000067A (he)
EA (1) EA020136B1 (he)
EC (1) ECSP11010859A (he)
ES (1) ES2551900T3 (he)
GE (1) GEP20135849B (he)
HK (2) HK1156627A1 (he)
HN (1) HN2011000629A (he)
HR (1) HRP20151410T1 (he)
HU (1) HUE026381T2 (he)
IL (1) IL211291A (he)
MA (1) MA32684B1 (he)
ME (1) ME01291A (he)
MX (1) MX2011002365A (he)
MY (1) MY150136A (he)
NI (1) NI201100052A (he)
NZ (1) NZ591449A (he)
PE (1) PE20110298A1 (he)
PL (1) PL2344474T3 (he)
PT (1) PT2344474E (he)
RS (1) RS54506B1 (he)
SI (1) SI2344474T1 (he)
SM (1) SMT201600005B (he)
SV (1) SV2011003849A (he)
TW (1) TWI434843B (he)
UY (1) UY32085A (he)
WO (1) WO2010026124A1 (he)
ZA (1) ZA201101118B (he)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
US20140249135A1 (en) * 2007-03-01 2014-09-04 Novartis Ag Pim kinase inhibitors and methods of their use
ES2714092T3 (es) 2007-06-13 2019-05-27 Incyte Holdings Corp Uso de sales del inhibidor de quinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
NZ591449A (en) 2008-09-02 2012-12-21 Novartis Ag Picolinamide derivatives as kinase inhibitors
MX2011002367A (es) * 2008-09-02 2011-04-04 Novartis Ag Inhibidores de cinasa biciclicos.
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
UA106078C2 (uk) 2009-05-22 2014-07-25 Інсайт Корпорейшн 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI643857B (zh) 2010-03-10 2018-12-11 英塞特公司 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
KR101464060B1 (ko) * 2010-04-07 2014-11-20 에프. 호프만-라 로슈 아게 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
CN103080106A (zh) * 2010-07-06 2013-05-01 诺瓦提斯公司 用作激酶抑制剂的环醚化合物
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
US9284270B2 (en) 2011-02-14 2016-03-15 The Governers Of The University Of Alberta Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
US20120225061A1 (en) * 2011-03-04 2012-09-06 Matthew Burger Tetrasubstituted cyclohexyl compounds as kinase inhibitors
US9187486B2 (en) 2011-04-29 2015-11-17 Amgen Inc. Bicyclic pyridazine compounds as Pim inhibitors
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
DK2734205T3 (en) 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
US9453003B2 (en) * 2011-08-11 2016-09-27 Jikai Biosciences, Inc. Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
US9458151B2 (en) * 2011-08-11 2016-10-04 Jikai Biosciences, Inc. Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9173883B2 (en) * 2012-05-21 2015-11-03 Novartis Ag Ring-substituted N-pyridinyl amides as kinase inhibitors
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
LT2900657T (lt) 2012-09-26 2020-05-25 F. Hoffmann-La Roche Ag Cikliniai eterio pirazol-4-il-heterociklil-karboksamido junginiai ir jų naudojimo būdai
CN103724301A (zh) * 2012-10-10 2014-04-16 上海特化医药科技有限公司 (2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
NZ748448A (en) 2012-11-15 2019-12-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
KR102403306B1 (ko) 2013-01-15 2022-06-02 인사이트 홀딩스 코포레이션 Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물
TWI634121B (zh) 2013-03-06 2018-09-01 英塞特控股公司 用於製備ｊａｋ抑制劑之方法及中間物
US9113629B2 (en) * 2013-03-15 2015-08-25 Dow Agrosciences Llc 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides
KR20220103810A (ko) 2013-08-07 2022-07-22 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
CA2917936A1 (en) * 2013-08-08 2015-02-12 Novartis Ag Pim kinase inhibitor combinations
JP2016528298A (ja) 2013-08-23 2016-09-15 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JP2016538305A (ja) * 2013-11-27 2016-12-08 ノバルティス アーゲー Ｊａｋ、ｃｄｋおよびｐｉｍの阻害剤を含む組合せ療法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
SI3116909T1 (sl) 2014-03-14 2020-03-31 Novartis Ag Molekule protiteles na LAG-3 in njih uporaba
EP3119775B1 (en) 2014-03-18 2019-11-06 F. Hoffmann-La Roche AG Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
JP2017535528A (ja) 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
JP6878405B2 (ja) 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
CN105254624B (zh) * 2015-09-18 2019-08-09 上海吉铠医药科技有限公司 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用
CN105130959B (zh) * 2015-09-18 2018-08-03 上海吉铠医药科技有限公司 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CR20180234A (es) 2015-11-03 2018-09-11 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN107522695B (zh) * 2016-06-21 2018-09-14 上海方予健康医药科技有限公司 一种pim激酶抑制剂的盐酸盐及其制备方法和用途
CN107522696B (zh) 2016-06-21 2019-02-19 上海方予健康医药科技有限公司 一种嘧啶类化合物的盐酸盐及其制备方法和用途
CN107519175A (zh) * 2016-06-21 2017-12-29 上海方予健康医药科技有限公司 一种嘧啶化合物或其盐在制备用于预防和/或治疗与flt3相关的疾病或障碍的药物中的应用
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
SG11201911936YA (en) 2017-06-30 2020-01-30 Bristol Myers Squibb Co Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
AU2019213665B2 (en) 2018-01-30 2024-06-13 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
HRP20220331T1 (hr) 2018-03-08 2022-05-13 Incyte Corporation Spojevi aminopirazin diola kao inhibitori pi3k-y
SI3773593T1 (sl) 2018-03-30 2024-08-30 Incyte Corporation Zdravljenje hidradenitisa suppurative z zaviralci jak
EP3773560A4 (en) 2018-04-13 2022-01-19 Sumitomo Dainippon Pharma Oncology, Inc. PIM KINASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND CANCER-ASSOCIATED FIBROSIS
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN110078706B (zh) * 2019-05-31 2022-02-01 浙江师范大学 一种伊马替尼衍生物及其制备方法和用途
CN110452164B (zh) * 2019-09-10 2022-07-22 上海皓鸿生物医药科技有限公司 Pim447关键中间体的制备方法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
WO2021091788A1 (en) * 2019-11-07 2021-05-14 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112915086B (zh) * 2021-01-27 2022-04-12 广州市力鑫药业有限公司 一种含有Akt靶向激酶抑制剂的药物组合物
WO2024097653A1 (en) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251134A4 (en) 2000-01-26 2003-01-29 Meiji Seika Kaisha NEW CARBAPENEM DERIVATIVES OF THE QUATERNARY SALT TYPE
JP2003520854A (ja) * 2000-01-27 2003-07-08 サイトビア インコーポレイテッド カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
CA2548172A1 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20060004197A1 (en) 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
ES2396913T3 (es) 2005-08-04 2013-03-01 Sirtris Pharmaceuticals, Inc. Compuestos moduladores de sirtuina
US8053454B2 (en) 2005-10-06 2011-11-08 Exelixis, Inc. Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
HRPK20050957B3 (en) * 2005-11-11 2008-09-30 Džanko Nikša Collapsible hanger
EP2078003B1 (en) 2006-10-31 2017-03-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
AR063531A1 (es) * 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
MX2009009304A (es) * 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
RU2474580C2 (ru) 2007-07-19 2013-02-10 Шеринг Корпорейшн Гетероциклические амидные соединения как ингибиторы протеинкиназ
US8445687B2 (en) 2007-09-10 2013-05-21 Cipla Limited Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process
UY31679A1 (es) * 2008-03-03 2009-09-30 Inhibidores de cinasa pim y metodos para su uso
NZ591449A (en) 2008-09-02 2012-12-21 Novartis Ag Picolinamide derivatives as kinase inhibitors
WO2011016234A1 (en) 2009-08-04 2011-02-10 Raqualia Pharma Inc. Picolinamide derivatives as ttx-s blockers
JP2014503000A (ja) 2011-01-21 2014-02-06 アッヴィ・インコーポレイテッド キナーゼのピコリンアミド阻害剤

Also Published As

Publication number Publication date
WO2010026124A1 (en) 2010-03-11
CN104311480A (zh) 2015-01-28
AU2009289319A1 (en) 2010-03-11
TWI434843B (zh) 2014-04-21
NZ591449A (en) 2012-12-21
KR20110048585A (ko) 2011-05-11
NI201100052A (es) 2011-09-03
TW201028393A (en) 2010-08-01
US20100056576A1 (en) 2010-03-04
IL211291A (he) 2014-05-28
CN102203079B (zh) 2014-12-10
CN102203079A (zh) 2011-09-28
JP5813701B2 (ja) 2015-11-17
CN103333157A (zh) 2013-10-02
ME01291A (me) 2013-06-20
MA32684B1 (fr) 2011-10-02
EP2344474B1 (en) 2015-09-23
EA020136B1 (ru) 2014-08-29
PL2344474T3 (pl) 2016-03-31
CA2734415A1 (en) 2010-03-11
BRPI0918268A2 (pt) 2020-11-17
CL2011000454A1 (es) 2011-09-30
PE20110298A1 (es) 2011-05-21
HRP20151410T1 (hr) 2016-01-15
SMT201600005B (it) 2016-02-25
RS54506B1 (en) 2016-06-30
US9079889B2 (en) 2015-07-14
JP2012501314A (ja) 2012-01-19
US20120134987A1 (en) 2012-05-31
US8592455B2 (en) 2013-11-26
DOP2011000067A (es) 2017-01-15
MX2011002365A (es) 2011-04-04
ECSP11010859A (es) 2011-04-29
MY150136A (en) 2013-11-29
EA201100425A1 (ru) 2011-10-31
PT2344474E (pt) 2015-12-28
CR20110114A (es) 2011-05-10
CO6351725A2 (es) 2011-12-20
GEP20135849B (en) 2013-06-10
US20150315150A1 (en) 2015-11-05
SV2011003849A (es) 2011-07-07
HN2011000629A (es) 2015-08-10
EP2344474A1 (en) 2011-07-20
UY32085A (es) 2010-03-26
SI2344474T1 (sl) 2015-12-31
HK1156627A1 (en) 2012-06-15
ES2551900T3 (es) 2015-11-24
DK2344474T3 (en) 2015-12-14
AU2009289319B2 (en) 2011-10-27
ZA201101118B (en) 2011-09-28
US8329732B2 (en) 2012-12-11
HUE026381T2 (en) 2016-06-28
US20140079693A1 (en) 2014-03-20
KR101345920B1 (ko) 2014-02-06
IL211291A0 (en) 2011-04-28
CA2734415C (en) 2016-07-26
JP2013231049A (ja) 2013-11-14
HK1162022A1 (en) 2012-08-17
AU2009289319C1 (en) 2013-12-05
BRPI0918268B1 (pt) 2021-08-03

Similar Documents

Publication Publication Date Title
JP5813701B2 (ja) キナーゼ阻害剤としてのピコリンアミド誘導体
JP5412448B2 (ja) Ｐｉｍキナーゼ阻害剤およびその使用方法
JP6204462B2 (ja) キナーゼ阻害剤としての新規環置換ｎ−ピリジニルアミド
US8829193B2 (en) PIM kinase inhibitors and methods of their use
JP2014506915A (ja) キナーゼ阻害剤としての四置換シクロヘキシル化合物
JP2012501312A (ja) 二環式キナーゼ阻害剤
JP2014506917A (ja) 新規キナーゼ阻害剤
WO2014033630A1 (en) Novel aminothiazole carboxamides as kinase inhibitors
AU2011265439B2 (en) Picolinamide derivatives as kinase inhibitors

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130625

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131111

R150 Certificate of patent or registration of utility model

Ref document number: 5412519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250